Skip to main content

Table 2 Summary of recommendations to managing immune-related adverse events. IrAEs: immune-related adverse events; IMP: investigational medicinal product

From: PRIME-HCC: phase Ib study of neoadjuvant ipilimumab and nivolumab prior to liver resection for hepatocellular carcinoma

irAE Supportive Care Intervention
Grade 1 Provide symptomatic treatment
Grade 2 Consider systemic corticosteroids in addition to appropriate symptomatic treatment.
Steroid taper should be considered once symptoms improve to Grade 1 or less and tapered over at least 4 weeks.
Grade 3 and Grade 4 Systemic corticosteroids are indicated in addition to appropriate symptomatic treatment. May utilize 1 to 2 mg/kg prednisone or equivalent per day.
Steroid taper should be considered once symptoms improve to Grade 1 or less and tapered over at least 4 weeks.
Consider referral to organ-specific specialist (i.e. gastroenterologist, hepatologist, respiratory physician, endocrinologist) for any grade 3–4 irAEs, in order to evaluate substitution treatments and immune-modulating agents, such as anti-TNFα of other immune suppressants.